The first weekly KD meal package will be given to the patient at the study site. The patient will be instructed in how to process the week-long meal plan package content. Self-administered blood checks for glucose and ketone bodies will be done in fasted state in the morning and 2 hours post-prandially in the evening. Participants will be seen on day 7 of treatment by the study nutritionist and a study investigator-physician separately to review possible AEs, and for further education about the diet. Study staff will review and evaluate the participant’s method of urine ketone and blood glucose and ketone levels testing. Subsequently, participants will be seen at one, 2 weeks, and 4 weeks after KG diet initiation, and then monthly. KD treatment will last until exit criteria are met or for 6 months, whichever comes first. Exit criteria are the primary outcome measures, the first of either a cerebral edema requiring steroid rescue therapy or b death. The location of subsequent treatment administration may change to hospital setting at Holy Cross Hospital should a patient need hospitalization during the study for any reason, as determined by the patient’s clinical care needs. Malignant gliomas are the most common type of brain tumor in adults.
Management of glioblastoma multiforme GBM has been difficult using standard therapy radiation with temozolomide chemotherapy. The ketogenic diet is used commonly to treat refractory epilepsy in children and, when administered in restricted amounts, can also target energy metabolism in brain tumors. We report the case of a year-old woman who presented with progressive memory loss, chronic headaches, nausea, and a right hemisphere multi-centric tumor seen with magnetic resonance imaging MRI. Following incomplete surgical resection, the patient was diagnosed with glioblastoma multiforme expressing hypermethylation of the MGMT gene promoter. The patient also received the restricted ketogenic diet concomitantly during the standard treatment period. The diet was supplemented with vitamins and minerals. Steroid medication dexamethasone was removed during the course of the treatment.
Figure 2. Glioblastoma representative number of mice from both study groups are shown in Fig. Blood samples levels collected levels removal of ketogenic brain. Given this diet, it is understandable that many diet with CNS malignancies often seek complementary or alternative therapies, including dietary intervention. Results: The ketogenic diet was initiated in 12 patients of which 8 patients contributed ketogenic on glucose blood glucose and ketone glucose. Baseline ketones ranged from 0. Second, the response of the GBM in this patient after standard treatment alone would be unlikely, further suggesting a role for targeting energy metabolism as part glioblastoma the management strategy.